L'objectif du projet est de vérifier la capacité du test Guardant Health 360 à détecter les tumeursréfractaires au traitement un mois après le début d'un traitement par hormonothérapie +inhibiteur de CDH4/6

Etude rétrospective de l’efficacité des sels de platine chez les patients atteints de cancer de la prostate métastatique résistant à la castration avec une mutation d’un des gènes de réparation de l’ADN.

Impact of the histological margin quality at initial surgery (R0 from the outset vs. R0 after revision surgery) on local relapse-free survival;

a. Impact of the histological margin quality at initial treatment (R0 from the outset vs. R0 after revision surgery) on overall survival.

b. Impact of the histological margin quality at initial surgery (R0 vs R1 vs R2 from the first surgical sequence (before any revision)) on overall survival.

c. Impact of the histological margin quality at initial surgery (R0 vs R1 vs R2 from the first surgical sequence (before any revision)) on local relapse-free survival.

d. Impact of the histological margin quality at initial surgery (R0 initial surgery with or without re-excision) on overall survival.

e. Impact of the histological margin quality at initial surgery (R0 initial surgery with or without re-excision) on local relapse-free survival.

f. Determination of initial treatment parameters which are prognostic for local relapse-free survival : histological subtype, size of tumor, grade, site of tumor, radiation area, biopsy before surgery, pre-operative imaging, neoadjuvant treatment before surgery, quality of first surgery, re-excision, surgeon inside or outside network, early metastasis.

g. Determination of initial treatment parameters which are prognostic for overall survival : histological subtype, size of tumor, grade, site of tumor, radiation area, biopsy before surgery, pre-operative imaging, neoadjuvant treatment before surgery, quality of first surgery, re-excision, surgeon inside or outside network, early metastasis. a. Impact of the histological margin quality at initial treatment (R0 from the outset vs. R0 after revision surgery) on overall survival.

b. Impact of the histological margin quality at initial surgery (R0 vs R1 vs R2 from the first surgical sequence (before any revision)) on overall survival.

c. Impact of the histological margin quality at initial surgery (R0 vs R1 vs R2 from the first surgical sequence (before any revision)) on local relapse-free survival.

d. Impact of the histological margin quality at initial surgery (R0 initial surgery with or without re-excision) on overall survival.

e. Impact of the histological margin quality at initial surgery (R0 initial surgery with or without re-excision) on local relapse-free survival.

f. Determination of initial treatment parameters which are prognostic for local relapse-free survival : histological subtype, size of tumor, grade, site of tumor, radiation area, biopsy before surgery, pre-operative imaging, neoadjuvant treatment before surgery, quality of first surgery, re-excision, surgeon inside or outside network, early metastasis.

g. Determination of initial treatment parameters which are prognostic for overall survival : histological subtype, size of tumor, grade, site of tumor, radiation area, biopsy before surgery, pre-operative imaging, neoadjuvant treatment before surgery, quality of first surgery, re-excision, surgeon inside or outside network, early metastasis. a. Impact of the histological margin quality at initial treatment (R0 from the outset vs. R0 after revision surgery) on overall survival.

b. Impact of the histological margin quality at initial surgery (R0 vs R1 vs R2 from the first surgical sequence (before any revision)) on overall survival.

c. Impact of the histological margin quality at initial surgery (R0 vs R1 vs R2 from the first surgical sequence (before any revision)) on local relapse-free survival.

d. Impact of the histological margin quality at initial surgery (R0 initial surgery with or without re-excision) on overall survival.

e. Impact of the histological margin quality at initial surgery (R0 initial surgery with or without re-excision) on local relapse-free survival.

f. Determination of initial treatment parameters which are prognostic for local relapse-free survival : histological subtype, size of tumor, grade, site of tumor, radiation area, biopsy before surgery, pre-operative imaging, neoadjuvant treatment before surgery, quality of first surgery, re-excision, surgeon inside or outside network, early metastasis.

g. Determination of initial treatment parameters which are prognostic for overall survival : histological subtype, size of tumor, grade, site of tumor, radiation area, biopsy before surgery, pre-operative imaging, neoadjuvant treatment before surgery, quality of first surgery, re-excision, surgeon inside or outside network, early metastasis. a. Impact of the histological margin quality at initial treatment (R0 from the outset vs. R0 after revision surgery) on overall survival.

b. Impact of the histological margin quality at initial surgery (R0 vs R1 vs R2 from the first surgical sequence (before any revision)) on overall survival.

c. Impact of the histological margin quality at initial surgery (R0 vs R1 vs R2 from the first surgical sequence (before any revision)) on local relapse-free survival.

d. Impact of the histological margin quality at initial surgery (R0 initial surgery with or without re-excision) on overall survival.

e. Impact of the histological margin quality at initial surgery (R0 initial surgery with or without re-excision) on local relapse-free survival.

f. Determination of initial treatment parameters which are prognostic for local relapse-free survival : histological subtype, size of tumor, grade, site of tumor, radiation area, biopsy before surgery, pre-operative imaging, neoadjuvant treatment before surgery, quality of first surgery, re-excision, surgeon inside or outside network, early metastasis.

g. Determination of initial treatment parameters which are prognostic for overall survival : histological subtype, size of tumor, grade, site of tumor, radiation area, biopsy before surgery, pre-operative imaging, neoadjuvant treatment before surgery, quality of first surgery, re-excision, surgeon inside or outside network, early metastasis.

Comparer le taux de séromes post-opératoires chez les patientes bénéficiant d’une mastectomie pour leur cancer du sein, en fonction du capitonnage ou non de la loge.

a) Comparer la survenue des complications post opératoires en fonction du capitonnage ou non de la loge b) Comparer la durée du séjour pour mastectomie en fonction du capitonnage ou non de la loge c) Comparer le nombre de consultations pour ponctions de sérome en fonction du capitonnage de la loge ou non d) Comparer les signes fonctionnels douleur et mobilité articulaire post-opératoire en fonction du capitonnage de la loge ou non

L’objectif principal est d’évaluer la survie globale avant et après l’introduction de l’immunothérapie chez les patients avec un CBNPC avancés.- SGCBNPCAI1

Le chercheur a pour objectif d'utiliser les données afin d'identifier des anomalies communes aux cancers bronchiques de patients qui présentent des métastases cérébrales, ceci afin de mieux prédire la survenue de cette complication et de mieux la traiter.

Le chercheur a pour objectif d'utiliser les données afin d'identifier des anomalies communes aux cancers bronchiques de patients qui présentent des métastases cérébrales, ceci afin de mieux prédire la survenue de cette complication et de mieux la traiter.

L’objectif principal est de comparer le taux de contrôle local 6 mois après curiethérapie utéro-vaginale entre PDR (Pulsed Dose Rate) et HDD (Haute Débit de Dose).

Objectif principal : Description du pronostic et des facteurs faisant varier le pronostic chez les patients âgés porteurs d'un cancer ORL

Plusieurs indicateurs pronostiques seront étudiés : ● Survie observé ● Survie nette ● Survie sans récidive locorégionale ● Survie sans récidive

Facteurs ayant un impact sur le pronostic : ▪ Age; ▪ sexe; ▪ Comorbidité (index de Charlson); ▪ Traitement optimal ou négocié au vu de l'état général ou du bilan onco gériatrique; ▪ Bilan biologique ▪ G8

Objectif secondaires : Décrire le résultat thérapeutique : évalué sur les critères suivants : lieu de vie à 3 mois (domicile, hôpital, SSR), la réalisation d’une trachéotomie, type d’alimentation, tolérance des traitements réalisés

L'objectif du projet est de vérifier la capacité du test Guardant Health 360 à détecter les tumeurs réfractaires au traitement un mois après le début d'un traitement par hormonothérapie + inhibiteur de CDH4/6